CAMBRIDGE, MASS. – April 22, 2016 — Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
Mr. Karsen held leadership positions at Celgene Corporation, including Chief Operations Officer and Executive Vice President and most recently, Chief Executive Officer of Celgene’s cellular therapeutics division. Previously, Mr. Karsen was President and Chief Executive Officer of Pearl Therapeutics, Inc., a privately held biotechnology company subsequently acquired by AstraZeneca. He also held executive positions at Human Genome Sciences, Inc. (acquired by GlaxoSmithKline), Bristol- Myers Squibb, Genentech (a member of the Roche Group) and Abbott Laboratories. Currently, Mr. Karsen serves on the board of directors of OncoMed Pharmaceuticals, Voyager Therapeutics, Jounce Therapeutics, and Pliant Therapeutics. He also serves on the boards of the Gladstone Foundation and the Sonoma Land Trust. Mr. Karsen is a member of the board of directors of the Biotechnology Innovation Organization (BIO) and was a former member of the board of the Alliance for Regenerative Medicine (ARM).
Mr. Karsen holds a Bachelor of Sciences in Biological Sciences from the University of Illinois, Urbana-Champaign, a Master of Arts in Teaching of Biology from Duke University, and a Master of Management degree from Northwestern University’s Kellogg Graduate School of Management.
“Perry has demonstrated both operational and strategic acumen as a senior executive and as a Director in the biopharmaceutical industry,” says Nessan Bermingham, Ph.D., Founder and Chief Executive Officer, Intellia Therapeutics. “We look forward to his leadership and guidance as the chairman of our board.”
About Intellia Therapeutics
Intellia Therapeutics is a leading gene editing company focused on the development of proprietary products utilizing a recently developed biological tool known as the CRISPR/Cas9 system.